BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Frontage Laboratories CMC Services Meets Quality Milestone


1/18/2012 8:44:19 AM

January 18, 2012 -- Frontage Laboratories, Inc., a global pharmaceutical contract research organization (CRO), today celebrated another achievement in quality by meeting FDA standards for testing commercial products in its Chemistry, Manufacturing and Controls (CMC) labs for the fourth time in four years.

The company hosted an FDA inspector who completed the annual review of CMC Quality and Lab Systems with no Form 483 citations. As a result, the Exton, PA, facilities maintain certification as commercial testing labs.

“We make it a priority to build in quality from start to finish for every project,” said Song Li, PhD, Frontage Founder and CEO. “This compliance certification from FDA is continued proof that our quality systems are working and it gives added confidence to our current and new clients.”

The Frontage CMC division provides services in the areas of pharmaceutical API development and GMP manufacturing, analytical testing, formulation product development and manufacturing of clinical trial materials including Sterile (Injections and ophthalmic), Oral Solid (IR and CR), Topical, and High Potent products.

US Quality Certification Follows Similar Approval by EU Inspectors

This new FDA stamp of approval follows another recent quality achievement by Frontage. In November, the company completed a successful quality audit that certified regulatory compliance and enabled it to provide clinical trial materials for a client’s upcoming European Union (EU) clinical study.

Known as a Qualified Person (QP) Audit, the process validated that Frontage product development, analytical testing, manufacturing facilities, and quality systems are in compliance with EU Good Manufacturing Practices (GMPs). Just as in today’s FDA audit, there were no major observations noted by the QP inspector.

About Frontage

Frontage Laboratories, Inc. is a global contract research, development and manufacturing organization, offering a full range of pharmaceutical R&D services. Frontage operates in the US and China, using one seamless GXP platform. Frontage runs three Phase 1 Clinical units, a 72-bed Phase 1 Unit in Hackensack, NJ, a 120-bed Phase 1 Unit in Zhengzhou, Henan Province China, and a-80 bed Phase 1 Unit in Changchun, Jiling Province China. Frontage has an AALAC certified preclinical animal facility in Pennsylvania, where it also maintains bioanalytical and CMC facilities. In Shanghai and Beijing, China, the company also operates bioanalytical and CMC facilities. As a rapidly expanding CRO with ten years of success providing high-quality GXP services, Frontage has established an international standard in pharmaceutical product research, development, quality and management systems.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES